Silence Therapeutics GmbH
🇩🇪Germany
Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
Phase 1
Completed
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Drug: Atu027 & gemcitabine in lead in safety periodDrug: Atu027 & gemcitabine in treatment arm 1Drug: Atu027 & gemcitabine in treatment arm 2
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Silence Therapeutics GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT01808638
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin Charité Centrum für Tumormedizin, Berlin, Germany
🇩🇪Klinikum Dortmund gGmbH Medizinische Klinik Mitte, Dortmund, Germany
🇩🇪Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
Study With Atu027 in Patients With Advanced Solid Cancer
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Silence Therapeutics GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT00938574
- Locations
- 🇩🇪
Dept. of Hematology & Med. Oncology, Univ. of Bochum, Marienhospital Herne, Herne, Germany
News
No news found